首页 > 最新文献

Infectious Diseases of Poverty最新文献

英文 中文
Public and health professional epidemic risk perceptions in countries that are highly vulnerable to epidemics: a systematic review. 极易受流行病影响国家的公共和卫生专业人员对流行病风险的认识:系统审查。
IF 4.8 1区 医学 Q1 INFECTIOUS DISEASES Pub Date : 2022-01-06 DOI: 10.1186/s40249-021-00927-z
Nada Abdelmagid, Francesco Checchi, Bayard Roberts

Background: Risk communication interventions during epidemics aim to modify risk perceptions to achieve rapid shifts in population health behaviours. Exposure to frequent and often concurrent epidemics may influence how the public and health professionals perceive and respond to epidemic risks. This review aimed to systematically examine the evidence on risk perceptions of epidemic-prone diseases in countries highly vulnerable to epidemics.

Methods: We conducted a systematic review using PRISMA standards. We included peer-reviewed studies describing or measuring risk perceptions of epidemic-prone diseases among the general adult population or health professionals in 62 countries considered highly vulnerable to epidemics. We searched seven bibliographic databases and applied a four-stage screening and selection process, followed by quality appraisal. We conducted a narrative meta-synthesis and descriptive summary of the evidence, guided by the Social Amplification of Risk Framework.

Results: Fifty-six studies were eligible for the final review. They were conducted in eighteen countries and addressed thirteen epidemic-prone diseases. Forty-five studies were quantitative, six qualitative and five used mixed methods. Forty-one studies described epidemic risk perceptions in the general public and nineteen among health professionals. Perceived severity of epidemic-prone diseases appeared high across public and health professional populations. However, perceived likelihood of acquiring disease varied from low to moderate to high among the general public, and appeared consistently high amongst health professionals. Other occupational groups with high exposure to specific diseases, such as bushmeat handlers, reported even lower perceived likelihood than the general population. Among health professionals, the safety and effectiveness of the work environment and of the broader health system response influenced perceptions. Among the general population, disease severity, familiarity and controllability of diseases were influential factors. However, the evidence on how epidemic risk perceptions are formed or modified in these populations is limited.

Conclusions: The evidence affords some insights into patterns of epidemic risk perception and influencing factors, but inadequately explores what underlies perceptions and their variability, particularly among diseases, populations and over time. Approaches to defining and measuring epidemic risk perceptions are relatively underdeveloped.

背景:流行病期间的风险沟通干预措施旨在改变风险观念,实现人口健康行为的快速转变。经常和经常同时接触流行病可能会影响公众和卫生专业人员如何看待和应对流行病风险。本综述的目的是系统地审查在易受流行病影响的国家对易流行疾病的风险认知的证据。方法:采用PRISMA标准进行系统评价。我们纳入了同行评议的研究,这些研究描述或测量了62个被认为极易流行的国家的普通成年人或卫生专业人员对易流行疾病的风险认知。我们检索了7个书目数据库,并采用了四阶段筛选和选择过程,然后进行质量评估。在风险社会放大框架的指导下,我们对证据进行了叙述性综合和描述性总结。结果:56项研究符合最终审查的条件。它们在18个国家开展,涉及13种容易流行的疾病。45项研究是定量的,6项是定性的,5项是混合方法。41项研究描述了普通公众对流行病风险的看法,19项研究描述了卫生专业人员对流行病风险的看法。在公共和卫生专业人群中,易流行疾病的严重程度似乎很高。然而,一般公众对患病可能性的认识从低到中到高不等,在卫生专业人员中似乎一直很高。其他高暴露于特定疾病的职业群体,如丛林肉处理者,报告的感知可能性甚至低于一般人群。在卫生专业人员中,工作环境的安全性和有效性以及更广泛的卫生系统反应影响了他们的看法。在普通人群中,疾病严重程度、熟悉程度和疾病可控性是影响因素。然而,关于这些人群对流行病风险的认识是如何形成或改变的证据有限。结论:证据提供了对流行病风险认知模式和影响因素的一些见解,但没有充分探讨认知的基础及其可变性,特别是在疾病、人群和时间之间。界定和衡量流行病风险认知的方法相对不发达。
{"title":"Public and health professional epidemic risk perceptions in countries that are highly vulnerable to epidemics: a systematic review.","authors":"Nada Abdelmagid, Francesco Checchi, Bayard Roberts","doi":"10.1186/s40249-021-00927-z","DOIUrl":"10.1186/s40249-021-00927-z","url":null,"abstract":"<p><strong>Background: </strong>Risk communication interventions during epidemics aim to modify risk perceptions to achieve rapid shifts in population health behaviours. Exposure to frequent and often concurrent epidemics may influence how the public and health professionals perceive and respond to epidemic risks. This review aimed to systematically examine the evidence on risk perceptions of epidemic-prone diseases in countries highly vulnerable to epidemics.</p><p><strong>Methods: </strong>We conducted a systematic review using PRISMA standards. We included peer-reviewed studies describing or measuring risk perceptions of epidemic-prone diseases among the general adult population or health professionals in 62 countries considered highly vulnerable to epidemics. We searched seven bibliographic databases and applied a four-stage screening and selection process, followed by quality appraisal. We conducted a narrative meta-synthesis and descriptive summary of the evidence, guided by the Social Amplification of Risk Framework.</p><p><strong>Results: </strong>Fifty-six studies were eligible for the final review. They were conducted in eighteen countries and addressed thirteen epidemic-prone diseases. Forty-five studies were quantitative, six qualitative and five used mixed methods. Forty-one studies described epidemic risk perceptions in the general public and nineteen among health professionals. Perceived severity of epidemic-prone diseases appeared high across public and health professional populations. However, perceived likelihood of acquiring disease varied from low to moderate to high among the general public, and appeared consistently high amongst health professionals. Other occupational groups with high exposure to specific diseases, such as bushmeat handlers, reported even lower perceived likelihood than the general population. Among health professionals, the safety and effectiveness of the work environment and of the broader health system response influenced perceptions. Among the general population, disease severity, familiarity and controllability of diseases were influential factors. However, the evidence on how epidemic risk perceptions are formed or modified in these populations is limited.</p><p><strong>Conclusions: </strong>The evidence affords some insights into patterns of epidemic risk perception and influencing factors, but inadequately explores what underlies perceptions and their variability, particularly among diseases, populations and over time. Approaches to defining and measuring epidemic risk perceptions are relatively underdeveloped.</p>","PeriodicalId":13587,"journal":{"name":"Infectious Diseases of Poverty","volume":"11 1","pages":"4"},"PeriodicalIF":4.8,"publicationDate":"2022-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8731200/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39787677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prevalence of Schistosoma mono- and co-infections with multiple common parasites and associated risk factors and morbidity profile among adults in the Taabo health and demographic surveillance system, South-Central Côte d'Ivoire. Côte科特迪瓦中南部塔博卫生和人口监测系统中成人中单一血吸虫病和多种常见寄生虫合并感染的流行情况及相关危险因素和发病率概况
IF 8.1 1区 医学 Q1 INFECTIOUS DISEASES Pub Date : 2022-01-05 DOI: 10.1186/s40249-021-00925-1
Fidèle K Bassa, Ikenna C Eze, Rufin K Assaré, Clémence Essé, Siaka Koné, Félix Acka, Véronique Laubhouet-Koffi, Dinard Kouassi, Bassirou Bonfoh, Jürg Utzinger, Eliézer K N'Goran

Background: Schistosomiasis remains an important public health problem, also among adults, and infected individuals not treated serve as a reservoir for continued transmission. Despite this fact, evidence on the epidemiology of schistosomiasis in adults in Côte d'Ivoire is scanty. This study aimed to determine the prevalence and risk factors of Schistosoma infection and co-infection with other helminth species and Plasmodium among adults in the Taabo region in the south-central part of Côte d'Ivoire.

Methods: A cross-sectional survey was carried out in April and May 2017 in the frame of the "Côte d'Ivoire Dual Burden of Disease Study" (CoDuBu). A total of 901 randomly selected individuals, aged 18-90 years, provided blood, stool and urine samples for the diagnosis of malaria and helminth infections. Stool samples were subjected to the Kato-Katz technique for detection of Schistosoma mansoni and soil-transmitted helminth eggs, while urine samples were examined for eggs of Schistosoma haematobium and circulating cathodic antigen of S. mansoni. Risk factors and morbidity profiles were assessed using health examination and questionnaires. Multinomial logistic regressions were employed to identify risk factors and morbidity patterns associated with S. mansoni mono- and co-infections.

Results: The prevalence of S. mansoni and S. haematobium was 23.2% and 1.0%, respectively. Most S. mansoni were mono-infections (81.3%). Independent determinants of S. mansoni infection were young age, low socioeconomic status (mono- and co-infection) and poor hygiene practices (co-infection) (P < 0.05). S. mansoni infection was independently associated with higher pain and symptom scores (mono-infection), poor self-rated health and low healthcare use (co-infection) (P < 0.05).

Conclusions: This study showed that adults represent a substantial reservoir of S. mansoni. To sustain schistosomiasis control and improve people's wellbeing, it is important to expand preventive chemotherapy from school-aged children to adults, coupled with hygiene and health education.

背景:血吸虫病仍然是一个重要的公共卫生问题,在成人中也是如此,未得到治疗的感染者是继续传播的宿主。尽管如此,关于Côte科特迪瓦成人血吸虫病流行病学的证据很少。本研究旨在确定Côte科特迪瓦中南部塔博地区成人血吸虫感染及与其他寄生虫和疟原虫共感染的流行情况和危险因素。方法:在“Côte科特迪瓦双重疾病负担研究”(CoDuBu)框架下,于2017年4月和5月进行横断面调查。随机抽取901名年龄在18-90岁之间的个体,提供血液、粪便和尿液样本,用于诊断疟疾和寄生虫感染。粪便标本采用加藤-卡茨法检测曼氏血吸虫和土壤传播蠕虫虫卵,尿液标本检测血血吸虫虫卵和曼氏血吸虫循环阴极抗原。通过健康检查和问卷调查评估危险因素和发病率概况。采用多项逻辑回归来确定与曼氏单胞杆菌和合并感染相关的危险因素和发病率模式。结果:mansoni和haematobium的感染率分别为23.2%和1.0%。以单感染为主(81.3%)。mansoni感染的独立决定因素是年轻、低社会经济地位(单一感染和合并感染)和不良卫生习惯(合并感染)(P)。要持续控制血吸虫病,改善民生,必须将预防性化疗从学龄儿童扩大到成人,并辅以卫生和健康教育。
{"title":"Prevalence of Schistosoma mono- and co-infections with multiple common parasites and associated risk factors and morbidity profile among adults in the Taabo health and demographic surveillance system, South-Central Côte d'Ivoire.","authors":"Fidèle K Bassa,&nbsp;Ikenna C Eze,&nbsp;Rufin K Assaré,&nbsp;Clémence Essé,&nbsp;Siaka Koné,&nbsp;Félix Acka,&nbsp;Véronique Laubhouet-Koffi,&nbsp;Dinard Kouassi,&nbsp;Bassirou Bonfoh,&nbsp;Jürg Utzinger,&nbsp;Eliézer K N'Goran","doi":"10.1186/s40249-021-00925-1","DOIUrl":"https://doi.org/10.1186/s40249-021-00925-1","url":null,"abstract":"<p><strong>Background: </strong>Schistosomiasis remains an important public health problem, also among adults, and infected individuals not treated serve as a reservoir for continued transmission. Despite this fact, evidence on the epidemiology of schistosomiasis in adults in Côte d'Ivoire is scanty. This study aimed to determine the prevalence and risk factors of Schistosoma infection and co-infection with other helminth species and Plasmodium among adults in the Taabo region in the south-central part of Côte d'Ivoire.</p><p><strong>Methods: </strong>A cross-sectional survey was carried out in April and May 2017 in the frame of the \"Côte d'Ivoire Dual Burden of Disease Study\" (CoDuBu). A total of 901 randomly selected individuals, aged 18-90 years, provided blood, stool and urine samples for the diagnosis of malaria and helminth infections. Stool samples were subjected to the Kato-Katz technique for detection of Schistosoma mansoni and soil-transmitted helminth eggs, while urine samples were examined for eggs of Schistosoma haematobium and circulating cathodic antigen of S. mansoni. Risk factors and morbidity profiles were assessed using health examination and questionnaires. Multinomial logistic regressions were employed to identify risk factors and morbidity patterns associated with S. mansoni mono- and co-infections.</p><p><strong>Results: </strong>The prevalence of S. mansoni and S. haematobium was 23.2% and 1.0%, respectively. Most S. mansoni were mono-infections (81.3%). Independent determinants of S. mansoni infection were young age, low socioeconomic status (mono- and co-infection) and poor hygiene practices (co-infection) (P < 0.05). S. mansoni infection was independently associated with higher pain and symptom scores (mono-infection), poor self-rated health and low healthcare use (co-infection) (P < 0.05).</p><p><strong>Conclusions: </strong>This study showed that adults represent a substantial reservoir of S. mansoni. To sustain schistosomiasis control and improve people's wellbeing, it is important to expand preventive chemotherapy from school-aged children to adults, coupled with hygiene and health education.</p>","PeriodicalId":13587,"journal":{"name":"Infectious Diseases of Poverty","volume":"11 1","pages":"3"},"PeriodicalIF":8.1,"publicationDate":"2022-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8728899/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39785295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
The COVID-19 vaccination campaign in Bhutan: strategy and enablers. 不丹的COVID-19疫苗接种运动:战略和推动因素。
IF 8.1 1区 医学 Q1 INFECTIOUS DISEASES Pub Date : 2022-01-05 DOI: 10.1186/s40249-021-00929-x
Tsheten Tsheten, Phurpa Tenzin, Archie C A Clements, Darren J Gray, Lhawang Ugyel, Kinley Wangdi

Bhutan has reported a total of 2596 COVID-19 cases and three deaths as of September 15, 2021. With support from India, the United States, Denmark, the People's Republic of China, Croatia and other countries, Bhutan was able to conduct two rounds of nationwide vaccination campaign. While many countries struggle to overcome vaccine refusal or hesitancy due to complacency, a lack of trust, inconvenience and fear, escalated in some countries by anti-vaccine groups, Bhutan managed to inoculate more than 95% of its eligible populations in two rounds of vaccination campaign. Enabling factors of this successful vaccination campaign were strong national leadership, a well-coordinated national preparedness plan, and high acceptability of vaccine due to effective mass communication and social engagement led by religious figures, volunteers and local leaders. In this short report, we described the national strategic plan and enabling factors that led to the success of this historical vaccination campaign.

截至2021年9月15日,不丹共报告了2596例COVID-19病例和3例死亡。在印度、美国、丹麦、中华人民共和国、克罗地亚和其他国家的支持下,不丹能够开展两轮全国性的疫苗接种运动。虽然许多国家努力克服由于自满、缺乏信任、不便和恐惧而导致的拒绝接种疫苗或犹豫不决,但在一些国家,反疫苗团体加剧了这种情况,不丹在两轮疫苗接种运动中成功地为95%以上的合格人口接种了疫苗。这一成功的疫苗接种运动的有利因素是强有力的国家领导、协调良好的国家防备计划,以及由于宗教人士、志愿者和地方领导人领导的有效的大众传播和社会参与,疫苗的高度可接受性。在这份简短的报告中,我们描述了导致这一历史性疫苗接种运动取得成功的国家战略计划和促成因素。
{"title":"The COVID-19 vaccination campaign in Bhutan: strategy and enablers.","authors":"Tsheten Tsheten,&nbsp;Phurpa Tenzin,&nbsp;Archie C A Clements,&nbsp;Darren J Gray,&nbsp;Lhawang Ugyel,&nbsp;Kinley Wangdi","doi":"10.1186/s40249-021-00929-x","DOIUrl":"https://doi.org/10.1186/s40249-021-00929-x","url":null,"abstract":"<p><p>Bhutan has reported a total of 2596 COVID-19 cases and three deaths as of September 15, 2021. With support from India, the United States, Denmark, the People's Republic of China, Croatia and other countries, Bhutan was able to conduct two rounds of nationwide vaccination campaign. While many countries struggle to overcome vaccine refusal or hesitancy due to complacency, a lack of trust, inconvenience and fear, escalated in some countries by anti-vaccine groups, Bhutan managed to inoculate more than 95% of its eligible populations in two rounds of vaccination campaign. Enabling factors of this successful vaccination campaign were strong national leadership, a well-coordinated national preparedness plan, and high acceptability of vaccine due to effective mass communication and social engagement led by religious figures, volunteers and local leaders. In this short report, we described the national strategic plan and enabling factors that led to the success of this historical vaccination campaign.</p>","PeriodicalId":13587,"journal":{"name":"Infectious Diseases of Poverty","volume":"11 1","pages":"6"},"PeriodicalIF":8.1,"publicationDate":"2022-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8727980/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39876478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 10
Infectious Diseases of Poverty: progress achieved during the decade gone and perspectives for the future. 贫穷传染病:过去十年取得的进展和对未来的展望。
IF 8.1 1区 医学 Q1 INFECTIOUS DISEASES Pub Date : 2022-01-04 DOI: 10.1186/s40249-021-00931-3
Xiao-Nong Zhou
{"title":"Infectious Diseases of Poverty: progress achieved during the decade gone and perspectives for the future.","authors":"Xiao-Nong Zhou","doi":"10.1186/s40249-021-00931-3","DOIUrl":"https://doi.org/10.1186/s40249-021-00931-3","url":null,"abstract":"","PeriodicalId":13587,"journal":{"name":"Infectious Diseases of Poverty","volume":"11 1","pages":"1"},"PeriodicalIF":8.1,"publicationDate":"2022-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8723998/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39785129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 8
The optimal vaccination strategy to control COVID-19: a modeling study in Wuhan City, China. 控制COVID-19的最佳疫苗接种策略:中国武汉市的模型研究
IF 8.1 1区 医学 Q1 INFECTIOUS DISEASES Pub Date : 2021-12-28 DOI: 10.1186/s40249-021-00922-4
Ze-Yu Zhao, Yan Niu, Li Luo, Qing-Qing Hu, Tian-Long Yang, Mei-Jie Chu, Qiu-Ping Chen, Zhao Lei, Jia Rui, Cheng-Long Song, Sheng-Nan Lin, Yao Wang, Jing-Wen Xu, Yuan-Zhao Zhu, Xing-Chun Liu, Meng Yang, Jie-Feng Huang, Wei-Kang Liu, Bin Deng, Chan Liu, Zhuo-Yang Li, Pei-Hua Li, Yan-Hua Su, Ben-Hua Zhao, Wen-Long Huang, Roger Frutos, Tian-Mu Chen

Background: Reaching optimal vaccination rates is an essential public health strategy to control the coronavirus disease 2019 (COVID-19) pandemic. This study aimed to simulate the optimal vaccination strategy to control the disease by developing an age-specific model based on the current transmission patterns of COVID-19 in Wuhan City, China.

Methods: We collected two indicators of COVID-19, including illness onset data and age of confirmed case in Wuhan City, from December 2, 2019, to March 16, 2020. The reported cases were divided into four age groups: group 1, ≤ 14 years old; group 2, 15 to 44 years old; group 3, 44 to 64 years old; and group 4, ≥ 65 years old. An age-specific susceptible-exposed-symptomatic-asymptomatic-recovered/removed model was developed to estimate the transmissibility and simulate the optimal vaccination strategy. The effective reproduction number (Reff) was used to estimate the transmission interaction in different age groups.

Results: A total of 47 722 new cases were reported in Wuhan City from December 2, 2019, to March 16, 2020. Before the travel ban of Wuhan City, the highest transmissibility was observed among age group 2 (Reff = 4.28), followed by group 2 to 3 (Reff = 2.61), and group 2 to 4 (Reff = 1.69). China should vaccinate at least 85% of the total population to interrupt transmission. The priority for controlling transmission should be to vaccinate 5% to 8% of individuals in age group 2 per day (ultimately vaccinated 90% of age group 2), followed by 10% of age group 3 per day (ultimately vaccinated 90% age group 3). However, the optimal vaccination strategy for reducing the disease severity identified individuals ≥ 65 years old as a priority group, followed by those 45-64 years old.

Conclusions: Approximately 85% of the total population (nearly 1.2 billion people) should be vaccinated to build an immune barrier in China to safely consider removing border restrictions. Based on these results, we concluded that 90% of adults aged 15-64 years should first be vaccinated to prevent transmission in China.

背景:实现最佳疫苗接种率是控制2019冠状病毒病(COVID-19)大流行的一项重要公共卫生战略。本研究旨在通过基于中国武汉市当前COVID-19传播模式的年龄特异性模型,模拟控制疾病的最佳疫苗接种策略。方法:收集武汉市2019年12月2日至2020年3月16日确诊病例的发病资料和年龄两项COVID-19指标。报告病例分为4个年龄组:1组,≤14岁;第二组,15至44岁;第三组,44岁至64岁;第4组,≥65岁。建立了一个年龄特异性易感-暴露-有症状-无症状-恢复/去除模型来估计传播率并模拟最佳疫苗接种策略。利用有效繁殖数(Reff)估计不同年龄组间的传播相互作用。结果:2019年12月2日至2020年3月16日,武汉市共报告新发病例47 722例。武汉市旅行禁令实施前,2组传播率最高(ref = 4.28),其次是2 ~ 3组(ref = 2.61)和2 ~ 4组(ref = 1.69)。中国应至少为85%的人口接种疫苗,以阻断传播。控制传播的重点应是每天为第2组5%至8%的个体接种疫苗(最终为第2组90%的个体接种疫苗),其次是每天为第3组10%的个体接种疫苗(最终为第3组90%的个体接种疫苗)。然而,降低疾病严重程度的最佳疫苗接种策略将≥65岁的个体确定为优先群体,其次是45-64岁的个体。结论:中国约85%的人口(近12亿人)应接种疫苗,以建立免疫屏障,以安全考虑取消边境限制。基于这些结果,我们得出结论,在中国,90%的15-64岁成年人应首先接种疫苗以预防传播。
{"title":"The optimal vaccination strategy to control COVID-19: a modeling study in Wuhan City, China.","authors":"Ze-Yu Zhao,&nbsp;Yan Niu,&nbsp;Li Luo,&nbsp;Qing-Qing Hu,&nbsp;Tian-Long Yang,&nbsp;Mei-Jie Chu,&nbsp;Qiu-Ping Chen,&nbsp;Zhao Lei,&nbsp;Jia Rui,&nbsp;Cheng-Long Song,&nbsp;Sheng-Nan Lin,&nbsp;Yao Wang,&nbsp;Jing-Wen Xu,&nbsp;Yuan-Zhao Zhu,&nbsp;Xing-Chun Liu,&nbsp;Meng Yang,&nbsp;Jie-Feng Huang,&nbsp;Wei-Kang Liu,&nbsp;Bin Deng,&nbsp;Chan Liu,&nbsp;Zhuo-Yang Li,&nbsp;Pei-Hua Li,&nbsp;Yan-Hua Su,&nbsp;Ben-Hua Zhao,&nbsp;Wen-Long Huang,&nbsp;Roger Frutos,&nbsp;Tian-Mu Chen","doi":"10.1186/s40249-021-00922-4","DOIUrl":"https://doi.org/10.1186/s40249-021-00922-4","url":null,"abstract":"<p><strong>Background: </strong>Reaching optimal vaccination rates is an essential public health strategy to control the coronavirus disease 2019 (COVID-19) pandemic. This study aimed to simulate the optimal vaccination strategy to control the disease by developing an age-specific model based on the current transmission patterns of COVID-19 in Wuhan City, China.</p><p><strong>Methods: </strong>We collected two indicators of COVID-19, including illness onset data and age of confirmed case in Wuhan City, from December 2, 2019, to March 16, 2020. The reported cases were divided into four age groups: group 1, ≤ 14 years old; group 2, 15 to 44 years old; group 3, 44 to 64 years old; and group 4, ≥ 65 years old. An age-specific susceptible-exposed-symptomatic-asymptomatic-recovered/removed model was developed to estimate the transmissibility and simulate the optimal vaccination strategy. The effective reproduction number (R<sub>eff</sub>) was used to estimate the transmission interaction in different age groups.</p><p><strong>Results: </strong>A total of 47 722 new cases were reported in Wuhan City from December 2, 2019, to March 16, 2020. Before the travel ban of Wuhan City, the highest transmissibility was observed among age group 2 (R<sub>eff</sub> = 4.28), followed by group 2 to 3 (R<sub>eff</sub> = 2.61), and group 2 to 4 (R<sub>eff</sub> = 1.69). China should vaccinate at least 85% of the total population to interrupt transmission. The priority for controlling transmission should be to vaccinate 5% to 8% of individuals in age group 2 per day (ultimately vaccinated 90% of age group 2), followed by 10% of age group 3 per day (ultimately vaccinated 90% age group 3). However, the optimal vaccination strategy for reducing the disease severity identified individuals ≥ 65 years old as a priority group, followed by those 45-64 years old.</p><p><strong>Conclusions: </strong>Approximately 85% of the total population (nearly 1.2 billion people) should be vaccinated to build an immune barrier in China to safely consider removing border restrictions. Based on these results, we concluded that 90% of adults aged 15-64 years should first be vaccinated to prevent transmission in China.</p>","PeriodicalId":13587,"journal":{"name":"Infectious Diseases of Poverty","volume":"10 1","pages":"140"},"PeriodicalIF":8.1,"publicationDate":"2021-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8712277/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39769655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 10
Current efforts towards safe and effective live attenuated vaccines against African swine fever: challenges and prospects. 目前研制安全有效的非洲猪瘟减毒活疫苗的努力:挑战与前景。
IF 8.1 1区 医学 Q1 INFECTIOUS DISEASES Pub Date : 2021-12-24 DOI: 10.1186/s40249-021-00920-6
Tao Wang, Rui Luo, Yuan Sun, Hua-Ji Qiu

Background: African swine fever (ASF) is a fatal hemorrhagic disease in domestic pigs and wild boar caused by African swine fever virus (ASFV). Since ASF has been introduced into Europe and Asia, the major pig-raising areas, posing a huge threat to the pork industry worldwide. Currently, prevention and control of ASF are basically dependent on strict biosecurity measures and stamping-out policy once ASF occurs.

Main text: The major risks of ASF spread are insufficient biosecurity measures and human behaviors. Therefore, a safe and effective vaccine seems to be a reasonable demand for the prevention and control of ASF. Due to the efficacy advantage over other types of vaccines, live attenuated vaccines (LAVs), especially virulence-associated genes deleted vaccines, are likely to be put into emergency and conditional use in restricted areas if ASF is out of control in a country with a huge pig population and pork consumption, like China. However, the safety, efficacy, and genetic stability of current candidate ASF LAVs require comprehensive clinical evaluations prior to country-wide field application. Several critical issues need to be addressed to commercialize an ideal ASF LAV, including a stable cell line for manufacturing vaccines, differentiation of infected from vaccinated animals (DIVA), and cross-protection from different genotypes.

Conclusion: A safe and effective DIVA vaccine and an accompanying diagnostic assay will facilitate the prevention, control, and eradication of ASF, which is quite challenging in the near future.

背景:非洲猪瘟(African swine fever, ASF)是由非洲猪瘟病毒(African swine fever virus, ASFV)引起的家猪和野猪的一种致死性出血性疾病。由于非洲猪瘟已传入欧洲和亚洲这两个主要养猪区,对全球猪肉产业构成了巨大威胁。目前,非洲猪瘟的防控基本依赖于严格的生物安全措施和发生后的扑灭政策。非洲猪瘟传播的主要风险是生物安全措施不足和人的行为。因此,研制安全有效的疫苗似乎是防控非洲猪瘟的合理要求。由于与其他类型疫苗相比,减毒活疫苗(lav),特别是毒力相关基因缺失疫苗,有可能在非洲猪瘟在中国这样一个养猪和猪肉消费巨大的国家失去控制时,在限制地区紧急和有条件地使用。然而,目前候选ASF lav的安全性、有效性和遗传稳定性需要在全国范围内应用前进行全面的临床评估。要使理想的非洲猪瘟LAV商业化,需要解决几个关键问题,包括用于生产疫苗的稳定细胞系、感染动物与接种动物的区分(DIVA)以及不同基因型的交叉保护。结论:一种安全有效的DIVA疫苗和相应的诊断方法将有助于预防、控制和根除非洲猪瘟,这在不久的将来是一项相当具有挑战性的工作。
{"title":"Current efforts towards safe and effective live attenuated vaccines against African swine fever: challenges and prospects.","authors":"Tao Wang,&nbsp;Rui Luo,&nbsp;Yuan Sun,&nbsp;Hua-Ji Qiu","doi":"10.1186/s40249-021-00920-6","DOIUrl":"https://doi.org/10.1186/s40249-021-00920-6","url":null,"abstract":"<p><strong>Background: </strong>African swine fever (ASF) is a fatal hemorrhagic disease in domestic pigs and wild boar caused by African swine fever virus (ASFV). Since ASF has been introduced into Europe and Asia, the major pig-raising areas, posing a huge threat to the pork industry worldwide. Currently, prevention and control of ASF are basically dependent on strict biosecurity measures and stamping-out policy once ASF occurs.</p><p><strong>Main text: </strong>The major risks of ASF spread are insufficient biosecurity measures and human behaviors. Therefore, a safe and effective vaccine seems to be a reasonable demand for the prevention and control of ASF. Due to the efficacy advantage over other types of vaccines, live attenuated vaccines (LAVs), especially virulence-associated genes deleted vaccines, are likely to be put into emergency and conditional use in restricted areas if ASF is out of control in a country with a huge pig population and pork consumption, like China. However, the safety, efficacy, and genetic stability of current candidate ASF LAVs require comprehensive clinical evaluations prior to country-wide field application. Several critical issues need to be addressed to commercialize an ideal ASF LAV, including a stable cell line for manufacturing vaccines, differentiation of infected from vaccinated animals (DIVA), and cross-protection from different genotypes.</p><p><strong>Conclusion: </strong>A safe and effective DIVA vaccine and an accompanying diagnostic assay will facilitate the prevention, control, and eradication of ASF, which is quite challenging in the near future.</p>","PeriodicalId":13587,"journal":{"name":"Infectious Diseases of Poverty","volume":"10 1","pages":"137"},"PeriodicalIF":8.1,"publicationDate":"2021-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8702042/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39758808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 16
Challenges in the control of COVID-19 outbreaks caused by the delta variant during periods of low humidity: an observational study in Sydney, Australia. 在低湿度期间控制由delta变异引起的COVID-19疫情的挑战:澳大利亚悉尼的一项观察研究
IF 8.1 1区 医学 Q1 INFECTIOUS DISEASES Pub Date : 2021-12-23 DOI: 10.1186/s40249-021-00926-0
Michael P Ward, Yuanhua Liu, Shuang Xiao, Zhijie Zhang

Background: Since the appearance of severe acute respiratory coronavirus 2 (SARS-CoV-2) and the coronavirus disease 2019 (COVID-19) pandemic, a growing body of evidence has suggested that weather factors, particularly temperature and humidity, influence transmission. This relationship might differ for the recently emerged B.1.617.2 (delta) variant of SARS-CoV-2. Here we use data from an outbreak in Sydney, Australia that commenced in winter and time-series analysis to investigate the association between reported cases and temperature and relative humidity.

Methods: Between 16 June and 10 September 2021, the peak of the outbreak, there were 31,662 locally-acquired cases reported in five local health districts of Sydney, Australia. The associations between daily 9:00 am and 3:00 pm temperature (°C), relative humidity (%) and their difference, and a time series of reported daily cases were assessed using univariable and multivariable generalized additive models and a 14-day exponential moving average. Akaike information criterion (AIC) and the likelihood ratio statistic were used to compare different models and determine the best fitting model. A sensitivity analysis was performed by modifying the exponential moving average.

Results: During the 87-day time-series, relative humidity ranged widely (< 30-98%) and temperatures were mild (approximately 11-17 °C). The best-fitting (AIC: 1,119.64) generalized additive model included 14-day exponential moving averages of 9:00 am temperature (P < 0.001) and 9:00 am relative humidity (P < 0.001), and the interaction between these two weather variables (P < 0.001). Humidity was negatively associated with cases no matter whether temperature was high or low. The effect of lower relative humidity on increased cases was more pronounced below relative humidity of about 70%; below this threshold, not only were the effects of humidity pronounced but also the relationship between temperature and cases of the delta variant becomes apparent.

Conclusions: We suggest that the control of COVID-19 outbreaks, specifically those due to the delta variant, is particularly challenging during periods of the year with lower relative humidity and warmer temperatures. In addition to vaccination, stronger implementation of other interventions such as mask-wearing and social distancing might need to be considered during these higher risk periods.

背景:自出现严重急性呼吸道冠状病毒2 (SARS-CoV-2)和2019冠状病毒病(COVID-19)大流行以来,越来越多的证据表明,天气因素,特别是温度和湿度,会影响传播。对于最近出现的B.1.617.2 (delta)变体SARS-CoV-2,这种关系可能有所不同。在这里,我们使用来自澳大利亚悉尼冬季爆发的数据和时间序列分析来调查报告病例与温度和相对湿度之间的关系。方法:在疫情高峰期2021年6月16日至9月10日期间,澳大利亚悉尼市5个地方卫生区共报告本地获得性病例31662例。采用单变量和多变量广义加性模型以及14天指数移动平均线,评估了每日9:00 am和3:00 pm温度(°C)、相对湿度(%)及其差异与每日报告病例时间序列之间的关系。采用赤池信息准则(Akaike information criterion, AIC)和似然比统计量对不同模型进行比较,确定最佳拟合模型。通过修正指数移动平均进行敏感性分析。结果:在87天的时间序列中,相对湿度的变化幅度很大。结论:我们认为,在一年中相对湿度较低和温度较高的时期,控制COVID-19疫情,特别是由delta变异引起的疫情尤其具有挑战性。除了疫苗接种外,在这些高风险时期可能需要考虑加强实施其他干预措施,如戴口罩和保持社交距离。
{"title":"Challenges in the control of COVID-19 outbreaks caused by the delta variant during periods of low humidity: an observational study in Sydney, Australia.","authors":"Michael P Ward,&nbsp;Yuanhua Liu,&nbsp;Shuang Xiao,&nbsp;Zhijie Zhang","doi":"10.1186/s40249-021-00926-0","DOIUrl":"https://doi.org/10.1186/s40249-021-00926-0","url":null,"abstract":"<p><strong>Background: </strong>Since the appearance of severe acute respiratory coronavirus 2 (SARS-CoV-2) and the coronavirus disease 2019 (COVID-19) pandemic, a growing body of evidence has suggested that weather factors, particularly temperature and humidity, influence transmission. This relationship might differ for the recently emerged B.1.617.2 (delta) variant of SARS-CoV-2. Here we use data from an outbreak in Sydney, Australia that commenced in winter and time-series analysis to investigate the association between reported cases and temperature and relative humidity.</p><p><strong>Methods: </strong>Between 16 June and 10 September 2021, the peak of the outbreak, there were 31,662 locally-acquired cases reported in five local health districts of Sydney, Australia. The associations between daily 9:00 am and 3:00 pm temperature (°C), relative humidity (%) and their difference, and a time series of reported daily cases were assessed using univariable and multivariable generalized additive models and a 14-day exponential moving average. Akaike information criterion (AIC) and the likelihood ratio statistic were used to compare different models and determine the best fitting model. A sensitivity analysis was performed by modifying the exponential moving average.</p><p><strong>Results: </strong>During the 87-day time-series, relative humidity ranged widely (< 30-98%) and temperatures were mild (approximately 11-17 °C). The best-fitting (AIC: 1,119.64) generalized additive model included 14-day exponential moving averages of 9:00 am temperature (P < 0.001) and 9:00 am relative humidity (P < 0.001), and the interaction between these two weather variables (P < 0.001). Humidity was negatively associated with cases no matter whether temperature was high or low. The effect of lower relative humidity on increased cases was more pronounced below relative humidity of about 70%; below this threshold, not only were the effects of humidity pronounced but also the relationship between temperature and cases of the delta variant becomes apparent.</p><p><strong>Conclusions: </strong>We suggest that the control of COVID-19 outbreaks, specifically those due to the delta variant, is particularly challenging during periods of the year with lower relative humidity and warmer temperatures. In addition to vaccination, stronger implementation of other interventions such as mask-wearing and social distancing might need to be considered during these higher risk periods.</p>","PeriodicalId":13587,"journal":{"name":"Infectious Diseases of Poverty","volume":"10 1","pages":"139"},"PeriodicalIF":8.1,"publicationDate":"2021-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8694908/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39625736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
Safety and immunogenicity of inactivated SARS-CoV-2 vaccine in high-risk occupational population: a randomized, parallel, controlled clinical trial. 高危职业人群接种 SARS-CoV-2 灭活疫苗的安全性和免疫原性:随机、平行、对照临床试验。
IF 8.1 1区 医学 Q1 INFECTIOUS DISEASES Pub Date : 2021-12-22 DOI: 10.1186/s40249-021-00924-2
Yongliang Feng, Jing Chen, Tian Yao, Yue Chang, Xiaoqing Li, Rongqin Xing, Hong Li, Ruixue Xie, Xiaohong Zhang, Zhiyun Wei, Shengcai Mu, Ling Liu, Lizhong Feng, Suping Wang

Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (COVID-19) have a substantial burden on health-care systems around the world. This is a randomized parallel controlled trial for assessment of the immunogenicity and safety of an inactivated SARS-CoV-2 vaccine, aiming to determine an appropriate vaccination interval of the vaccine for high-risk occupational population.

Methods: In an ongoing randomized, parallel, controlled phase IV trial between January and May 2021 in Taiyuan City, Shanxi Province, China, we randomly assigned the airport ground staff and public security officers aged 18 to 59 years to receive two doses of inactivated SARS-CoV-2 vaccine at 14 days, 21 days, or 28 days. The serum neutralizing antibody to live SARS-CoV-2 was performed at baseline and 28 days after immunization. Long-term data are being collected. The primary immunogenicity endpoints were neutralization antibody seroconversion and geometric mean titer (GMT) at 28 days after the second dose. Analysis of variance (ANOVA), chi-square, and logistic regression analysis were used for data analysis.

Results: A total of 809 participants underwent randomization and received two doses of injections: 270, 270, 269 in the 0-14, 0-21, and 0-28 vaccination group, respectively. By day 28 after the second injection, SARS-CoV-2 neutralizing antibody of GMT was 98.4 (95% CI: 88.4-108.4) in the 0-14 group, which was significantly lower compared with 134.4 (95% CI: 123.1-145.7) in the 0-21 group (P < 0.001 vs 0-14 group) and 145.5 (95% CI: 131.3-159.6) in the 0-28 group (P < 0.001 vs 0-14 group), resulting in the seroconversion rates to neutralizing antibodies (GMT ≥ 16) of 100.0% for all three groups, respectively. The intention-to-treat (ITT) analysis yielded similar results. All reported adverse reactions were mild.

Conclusions: Both a two-dose of inactivated SARS-CoV-2 vaccine at 0-21 days and 0-28 days regimens significantly improved SARS-CoV-2 neutralizing antibody level compared to the 0-14 days regimen in high-risk occupational population, with seroconversion rates of 100.0%.

Trial registration: Chinese Clinical Trial Registry, ChiCTR2100041705, ChiCTR2100041706. Registered 1 January 2021, www.chictr.org.cn .

背景:严重急性呼吸系统综合征冠状病毒 2(SARS-CoV-2)感染及其引发的冠状病毒病 2019(COVID-19)给世界各地的医疗保健系统造成了沉重负担。这是一项评估 SARS-CoV-2 灭活疫苗免疫原性和安全性的随机平行对照试验,旨在确定高危职业人群接种该疫苗的适当间隔时间:在 2021 年 1 月至 5 月期间正在山西省太原市进行的一项随机、平行、对照 IV 期试验中,我们随机分配了 18 至 59 岁的机场地勤人员和公安人员,分别在 14 天、21 天或 28 天接种两剂 SARS-CoV-2 灭活疫苗。在基线和免疫接种后 28 天进行了 SARS-CoV-2 活疫苗血清中和抗体检测。目前正在收集长期数据。主要免疫原性终点是中和抗体血清转换率和第二剂后 28 天的几何平均滴度 (GMT)。数据分析采用了方差分析(ANOVA)、卡方差分析和逻辑回归分析:共有 809 名参与者进行了随机分组,并接受了两剂注射:0-14、0-21 和 0-28 疫苗接种组分别有 270 人、270 人和 269 人。在第二次注射后的第 28 天,0-14 组 GMT 的 SARS-CoV-2 中和抗体为 98.4(95% CI:88.4-108.4),明显低于 0-21 组的 134.4(95% CI:123.1-145.7)(P 结论:0-14 组的 SARS-CoV-2 中和抗体为 98.4(95% CI:88.4-108.4),明显低于 0-21 组的 134.4(95% CI:123.1-145.7):与0-14天接种方案相比,0-21天和0-28天接种两剂SARS-CoV-2灭活疫苗可明显提高高危职业人群的SARS-CoV-2中和抗体水平,血清转换率为100.0%:试验注册:中国临床试验注册中心,ChiCTR2100041705、ChiCTR2100041706。注册日期:2021 年 1 月 1 日,www.chictr.org.cn 。
{"title":"Safety and immunogenicity of inactivated SARS-CoV-2 vaccine in high-risk occupational population: a randomized, parallel, controlled clinical trial.","authors":"Yongliang Feng, Jing Chen, Tian Yao, Yue Chang, Xiaoqing Li, Rongqin Xing, Hong Li, Ruixue Xie, Xiaohong Zhang, Zhiyun Wei, Shengcai Mu, Ling Liu, Lizhong Feng, Suping Wang","doi":"10.1186/s40249-021-00924-2","DOIUrl":"10.1186/s40249-021-00924-2","url":null,"abstract":"<p><strong>Background: </strong>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (COVID-19) have a substantial burden on health-care systems around the world. This is a randomized parallel controlled trial for assessment of the immunogenicity and safety of an inactivated SARS-CoV-2 vaccine, aiming to determine an appropriate vaccination interval of the vaccine for high-risk occupational population.</p><p><strong>Methods: </strong>In an ongoing randomized, parallel, controlled phase IV trial between January and May 2021 in Taiyuan City, Shanxi Province, China, we randomly assigned the airport ground staff and public security officers aged 18 to 59 years to receive two doses of inactivated SARS-CoV-2 vaccine at 14 days, 21 days, or 28 days. The serum neutralizing antibody to live SARS-CoV-2 was performed at baseline and 28 days after immunization. Long-term data are being collected. The primary immunogenicity endpoints were neutralization antibody seroconversion and geometric mean titer (GMT) at 28 days after the second dose. Analysis of variance (ANOVA), chi-square, and logistic regression analysis were used for data analysis.</p><p><strong>Results: </strong>A total of 809 participants underwent randomization and received two doses of injections: 270, 270, 269 in the 0-14, 0-21, and 0-28 vaccination group, respectively. By day 28 after the second injection, SARS-CoV-2 neutralizing antibody of GMT was 98.4 (95% CI: 88.4-108.4) in the 0-14 group, which was significantly lower compared with 134.4 (95% CI: 123.1-145.7) in the 0-21 group (P < 0.001 vs 0-14 group) and 145.5 (95% CI: 131.3-159.6) in the 0-28 group (P < 0.001 vs 0-14 group), resulting in the seroconversion rates to neutralizing antibodies (GMT ≥ 16) of 100.0% for all three groups, respectively. The intention-to-treat (ITT) analysis yielded similar results. All reported adverse reactions were mild.</p><p><strong>Conclusions: </strong>Both a two-dose of inactivated SARS-CoV-2 vaccine at 0-21 days and 0-28 days regimens significantly improved SARS-CoV-2 neutralizing antibody level compared to the 0-14 days regimen in high-risk occupational population, with seroconversion rates of 100.0%.</p><p><strong>Trial registration: </strong>Chinese Clinical Trial Registry, ChiCTR2100041705, ChiCTR2100041706. Registered 1 January 2021, www.chictr.org.cn .</p>","PeriodicalId":13587,"journal":{"name":"Infectious Diseases of Poverty","volume":"10 1","pages":"138"},"PeriodicalIF":8.1,"publicationDate":"2021-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8692079/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39833906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cost yield of different treatment strategies against Clonorchis sinensis infection. 不同治疗策略对抗华支睾吸虫感染的成本收益。
IF 8.1 1区 医学 Q1 INFECTIOUS DISEASES Pub Date : 2021-12-22 DOI: 10.1186/s40249-021-00917-1
Men-Bao Qian, Chang-Hai Zhou, Hui-Hui Zhu, Ying-Dan Chen, Xiao-Nong Zhou
<p><strong>Background: </strong>Clonorchiasis is attributed to the ingestion of raw freshwater fish harboring Clonorchis sinensis. Morbidity control is targeted through the administration of antihelminthics. This study modelled the cost yield indicated by effectiveness and utility of different treatment strategies against clonorchiasis.</p><p><strong>Methods: </strong>About 1000 participants were enrolled from each of 14 counties selected from four provincial-level administrative divisions namely Guangxi, Guangdong, Heilongjiang and Jilin in 2017. Fecal examination was adopted to detect C. sinensis infection, while behavior of ingesting raw freshwater fish was enquired. Counties were grouped into four categories based on prevalence, namely low prevalence group (< 1%), moderate prevalence group (1-9.9%), high prevalence group (10-19.9%) and very high prevalence group (≥ 20%), while population were divided into three subgroups, namely children aged below 14 years old, adult female and adult male both aged over 14 years old. The average of cost effectiveness indicated by the cost to treat single infected cases with C. sinensis and of cost utility indicated by the cost to avoid per disability-adjusted life years (DALYs) caused by C. sinensis infection was calculated. Comparisons were performed between three treatment schedules, namely individual treatment, massive and selective chemotherapy, in which different endemic levels and populations were considered.</p><p><strong>Results: </strong>In selective chemotherapy strategy, the cost to treat single infected case in very high prevalence group was USD 10.6 in adult male, USD 11.6 in adult female, and USD 13.2 in children. The cost increased followed the decrease of endemic level. In massive chemotherapy strategy, the cost per infected case in very high prevalence group was USD 14.0 in adult male, USD 17.1 in adult female, USD 45.8 in children, which were also increased when the endemic level decreased. In individual treatment strategy, the cost was USD 12.2 in adult male, USD 15.0 in adult female and USD 41.5 in children in very high prevalence group; USD 19.2 in adult male, USD 34.0 in adult female, and USD 90.1 in children in high prevalence group; USD 30.4 in adult male, USD 50.5 in adult female and over USD 100 in children in moderate prevalence group; and over USD 400 in any population in low prevalence group. As to cost utility, the differences by treatment strategies, populations and endemic levels were similar to those in cost effectiveness.</p><p><strong>Conclusions: </strong>Both cost effectiveness and cost utility indicators are highly impacted by the prevalence and population, as well as the treatment schedules. Adults especially men in the areas with a prevalence over 10% should be prioritized, in which selective chemotherapy was best and massive chemotherapy was also cost effective. In moderate endemic areas, the yield is not ideal, but selective chemotherapy for adult male may also be ad
背景:华支睾吸虫病是由于摄入含有华支睾吸虫病的生淡水鱼引起的。发病率控制是通过使用抗寄生虫药来实现的。本研究模拟了不同治疗策略对华支睾吸虫病的有效性和效用所表明的成本收益。方法:2017年在广西、广东、黑龙江、吉林4个省级行政区的14个县中,每县约1000人入选。采用粪便检查检测中华梭菌感染,同时询问食生淡水鱼行为。结果:在选择性化疗方案中,非常高流行组单个感染病例的治疗费用为成年男性10.6美元,成年女性11.6美元,儿童13.2美元。随着流行程度的降低,成本也随之增加。在大剂量化疗方案中,高流行组成年男性每例感染的费用为14.0美元,成年女性为17.1美元,儿童为45.8美元,随着流行程度的降低而增加。在个体治疗策略中,非常高流行组成年男性的费用为12.2美元,成年女性为15.0美元,儿童为41.5美元;高流行组成年男性19.2美元,成年女性34.0美元,儿童90.1美元;中等流行组成年男性30.4美元,成年女性50.5美元,儿童100美元以上;在任何低患病率人群中均超过400美元。在成本效用方面,治疗策略、人群和流行程度之间的差异与成本效益方面的差异相似。结论:成本效益和成本效用指标均受患病率和人群以及治疗计划的高度影响。成人尤其是男性在患病率超过10%的地区应优先选择选择性化疗,大规模化疗也具有较好的成本效益。在中度流行地区,产量不理想,但也可采取选择性化疗对成年男性。在低流行地区,所有战略的成本都很高,需要制定新的战略。
{"title":"Cost yield of different treatment strategies against Clonorchis sinensis infection.","authors":"Men-Bao Qian,&nbsp;Chang-Hai Zhou,&nbsp;Hui-Hui Zhu,&nbsp;Ying-Dan Chen,&nbsp;Xiao-Nong Zhou","doi":"10.1186/s40249-021-00917-1","DOIUrl":"https://doi.org/10.1186/s40249-021-00917-1","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Clonorchiasis is attributed to the ingestion of raw freshwater fish harboring Clonorchis sinensis. Morbidity control is targeted through the administration of antihelminthics. This study modelled the cost yield indicated by effectiveness and utility of different treatment strategies against clonorchiasis.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;About 1000 participants were enrolled from each of 14 counties selected from four provincial-level administrative divisions namely Guangxi, Guangdong, Heilongjiang and Jilin in 2017. Fecal examination was adopted to detect C. sinensis infection, while behavior of ingesting raw freshwater fish was enquired. Counties were grouped into four categories based on prevalence, namely low prevalence group (&lt; 1%), moderate prevalence group (1-9.9%), high prevalence group (10-19.9%) and very high prevalence group (≥ 20%), while population were divided into three subgroups, namely children aged below 14 years old, adult female and adult male both aged over 14 years old. The average of cost effectiveness indicated by the cost to treat single infected cases with C. sinensis and of cost utility indicated by the cost to avoid per disability-adjusted life years (DALYs) caused by C. sinensis infection was calculated. Comparisons were performed between three treatment schedules, namely individual treatment, massive and selective chemotherapy, in which different endemic levels and populations were considered.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;In selective chemotherapy strategy, the cost to treat single infected case in very high prevalence group was USD 10.6 in adult male, USD 11.6 in adult female, and USD 13.2 in children. The cost increased followed the decrease of endemic level. In massive chemotherapy strategy, the cost per infected case in very high prevalence group was USD 14.0 in adult male, USD 17.1 in adult female, USD 45.8 in children, which were also increased when the endemic level decreased. In individual treatment strategy, the cost was USD 12.2 in adult male, USD 15.0 in adult female and USD 41.5 in children in very high prevalence group; USD 19.2 in adult male, USD 34.0 in adult female, and USD 90.1 in children in high prevalence group; USD 30.4 in adult male, USD 50.5 in adult female and over USD 100 in children in moderate prevalence group; and over USD 400 in any population in low prevalence group. As to cost utility, the differences by treatment strategies, populations and endemic levels were similar to those in cost effectiveness.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;Both cost effectiveness and cost utility indicators are highly impacted by the prevalence and population, as well as the treatment schedules. Adults especially men in the areas with a prevalence over 10% should be prioritized, in which selective chemotherapy was best and massive chemotherapy was also cost effective. In moderate endemic areas, the yield is not ideal, but selective chemotherapy for adult male may also be ad","PeriodicalId":13587,"journal":{"name":"Infectious Diseases of Poverty","volume":"10 1","pages":"136"},"PeriodicalIF":8.1,"publicationDate":"2021-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8693485/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39744626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Bioefficacy and durability of Olyset® Plus, a permethrin and piperonyl butoxide-treated insecticidal net in a 3-year long trial in Kenya. 在肯尼亚进行的一项为期3年的试验中,氯菊酯和胡椒酰丁醇处理的杀虫蚊帐Olyset®Plus的生物功效和耐久性。
IF 4.8 1区 医学 Q1 INFECTIOUS DISEASES Pub Date : 2021-12-20 DOI: 10.1186/s40249-021-00916-2
Paul M Gichuki, Luna Kamau, Kiambo Njagi, Solomon Karoki, Njoroge Muigai, Damaris Matoke-Muhia, Nabie Bayoh, Evan Mathenge, Rajpal S Yadav

Background: Long-lasting insecticide nets (LLINs) are a core malaria intervention. LLINs should retain efficacy against mosquito vectors for a minimum of three years. Efficacy and durability of Olyset® Plus, a permethrin and piperonyl butoxide (PBO) treated LLIN, was evaluated versus permethrin treated Olyset® Net. In the absence of WHO guidelines of how to evaluate PBO nets, and considering the manufacturer's product claim, Olyset® Plus was evaluated as a pyrethroid LLIN.

Methods: This was a household randomized controlled trial in a malaria endemic rice cultivation zone of Kirinyaga County, Kenya between 2014 and 2017. Cone bioassays and tunnel tests were done against Anopheles gambiae Kisumu. The chemical content, fabric integrity and LLIN survivorship were monitored. Comparisons between nets were tested for significance using the Chi-square test. Exact binomial distribution with 95% confidence intervals (95% CI) was used for percentages. The WHO efficacy criteria used were ≥ 95% knockdown and/or ≥ 80% mortality rate in cone bioassays and ≥ 80% mortality and/or ≥ 90% blood-feeding inhibition in tunnel tests.

Results: At 36 months, Olyset® Plus lost 52% permethrin and 87% PBO content; Olyset® Net lost 24% permethrin. Over 80% of Olyset® Plus and Olyset® Net passed the WHO efficacy criteria for LLINs up to 18 and 12 months, respectively. At month 36, 91.2% Olyset® Plus and 86.4% Olyset® Net survived, while 72% and 63% developed at least one hole. The proportionate Hole Index (pHI) values representing nets in good, serviceable and torn condition were 49.6%, 27.1% and 23.2%, respectively for Olyset® Plus, and 44.9%, 32.8% and 22.2%, respectively for Olyset® Net but were not significantly different.

Conclusions: Olyset® Plus retained efficacy above or close to the WHO efficacy criteria for about 2 years than Olyset® Net (1-1.5 years). Both nets did not meet the 3-year WHO efficacy criteria, and showed little attrition, comparable physical durability and survivorship, with 50% of Olyset® Plus having good and serviceable condition after 3 years. Better community education on appropriate use and upkeep of LLINs is essential to ensure effectiveness of LLIN based malaria interventions.

背景:长效杀虫剂蚊帐(LLINs)是一项核心的疟疾干预措施。杀虫剂对蚊虫媒介的效力应至少保持三年。对氯菊酯和胡椒酰丁醇(PBO)处理的LLIN与氯菊酯处理的Olyset®Net的有效性和持久性进行了评估。由于缺乏世卫组织关于如何评估PBO蚊帐的指导方针,并考虑到制造商的产品声明,Olyset®Plus被评估为拟除虫菊酯LLIN。方法:2014 - 2017年在肯尼亚Kirinyaga县疟疾流行水稻种植区进行家庭随机对照试验。对基苏木冈比亚按蚊进行了锥生物测定和隧道试验。监测化学成分、织物完整性和LLIN存活率。使用卡方检验检验网间比较的显著性。百分比采用精确二项分布,95%置信区间(95% CI)。使用的WHO疗效标准是锥体生物测定中敲除率≥95%和/或死亡率≥80%,隧道试验中死亡率≥80%和/或血供抑制率≥90%。结果:在36个月时,Olyset®Plus减少了52%的氯菊酯和87%的PBO含量;Olyset®Net减少了24%的氯菊酯。超过80%的Olyset®Plus和Olyset®Net分别通过了WHO针对LLINs长达18个月和12个月的疗效标准。在第36个月,91.2%的Olyset®Plus和86.4%的Olyset®Net成活率,72%和63%的Olyset®Net至少钻了一个井眼。Olyset®Plus的比例孔指数(pHI)值分别为49.6%、27.1%和23.2%,Olyset®Net的比例孔指数(pHI)值分别为44.9%、32.8%和22.2%。结论:Olyset®Plus比Olyset®Net(1-1.5年)保持高于或接近WHO疗效标准约2年。这两种蚊帐都没有达到WHO的3年疗效标准,磨损很小,具有相当的物理耐久性和生存率,50%的Olyset®Plus在3年后具有良好和可使用的状态。更好地开展关于适当使用和维护LLIN的社区教育,对于确保基于LLIN的疟疾干预措施的有效性至关重要。
{"title":"Bioefficacy and durability of Olyset<sup>®</sup> Plus, a permethrin and piperonyl butoxide-treated insecticidal net in a 3-year long trial in Kenya.","authors":"Paul M Gichuki, Luna Kamau, Kiambo Njagi, Solomon Karoki, Njoroge Muigai, Damaris Matoke-Muhia, Nabie Bayoh, Evan Mathenge, Rajpal S Yadav","doi":"10.1186/s40249-021-00916-2","DOIUrl":"10.1186/s40249-021-00916-2","url":null,"abstract":"<p><strong>Background: </strong>Long-lasting insecticide nets (LLINs) are a core malaria intervention. LLINs should retain efficacy against mosquito vectors for a minimum of three years. Efficacy and durability of Olyset<sup>®</sup> Plus, a permethrin and piperonyl butoxide (PBO) treated LLIN, was evaluated versus permethrin treated Olyset<sup>®</sup> Net. In the absence of WHO guidelines of how to evaluate PBO nets, and considering the manufacturer's product claim, Olyset<sup>®</sup> Plus was evaluated as a pyrethroid LLIN.</p><p><strong>Methods: </strong>This was a household randomized controlled trial in a malaria endemic rice cultivation zone of Kirinyaga County, Kenya between 2014 and 2017. Cone bioassays and tunnel tests were done against Anopheles gambiae Kisumu. The chemical content, fabric integrity and LLIN survivorship were monitored. Comparisons between nets were tested for significance using the Chi-square test. Exact binomial distribution with 95% confidence intervals (95% CI) was used for percentages. The WHO efficacy criteria used were ≥ 95% knockdown and/or ≥ 80% mortality rate in cone bioassays and ≥ 80% mortality and/or ≥ 90% blood-feeding inhibition in tunnel tests.</p><p><strong>Results: </strong>At 36 months, Olyset<sup>®</sup> Plus lost 52% permethrin and 87% PBO content; Olyset<sup>®</sup> Net lost 24% permethrin. Over 80% of Olyset<sup>®</sup> Plus and Olyset<sup>®</sup> Net passed the WHO efficacy criteria for LLINs up to 18 and 12 months, respectively. At month 36, 91.2% Olyset<sup>®</sup> Plus and 86.4% Olyset<sup>®</sup> Net survived, while 72% and 63% developed at least one hole. The proportionate Hole Index (pHI) values representing nets in good, serviceable and torn condition were 49.6%, 27.1% and 23.2%, respectively for Olyset<sup>®</sup> Plus, and 44.9%, 32.8% and 22.2%, respectively for Olyset<sup>®</sup> Net but were not significantly different.</p><p><strong>Conclusions: </strong>Olyset<sup>®</sup> Plus retained efficacy above or close to the WHO efficacy criteria for about 2 years than Olyset<sup>®</sup> Net (1-1.5 years). Both nets did not meet the 3-year WHO efficacy criteria, and showed little attrition, comparable physical durability and survivorship, with 50% of Olyset<sup>®</sup> Plus having good and serviceable condition after 3 years. Better community education on appropriate use and upkeep of LLINs is essential to ensure effectiveness of LLIN based malaria interventions.</p>","PeriodicalId":13587,"journal":{"name":"Infectious Diseases of Poverty","volume":"10 1","pages":"135"},"PeriodicalIF":4.8,"publicationDate":"2021-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8691082/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39742581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Infectious Diseases of Poverty
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1